Our Pricing

£20 off Ozempic & Mounjaro - Use Code WEIGHTLOSSNEW

Published on: June 03, 2026

Searching for £20 off Mounjaro and Ozempic UK deals? Cured Pharmacy offers genuine UK-licensed weight loss injections with transparent upfront pricing, free clinical assessments by UK prescribers, and discreet next-day delivery. Use code WEIGHTLOSSNEW at checkout to save on your first order, subject to prescriber approval.

How to Claim Your £20 discount on Weight Loss Injections

Claiming your discount is straightforward. Start by completing our free online consultation — it takes under three minutes and is reviewed by a UK-registered prescriber from our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Once your treatment is approved, simply enter code WEIGHTLOSSNEW at checkout to receive your discount on eligible weight loss medications.

This offer applies to first orders of Mounjaro and other prescription weight loss treatments, subject to clinical suitability. All medications dispensed by Cured Pharmacy are genuine UK-licensed products sourced through regulated channels and comply with MHRA standards. Your prescription will be dispensed from our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging.

Understanding Mounjaro: The UK's Most Effective Weight Loss Injection

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway medications, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing superior weight loss outcomes compared to earlier generation treatments.

In the landmark SURMOUNT-1 trial, participants taking the highest dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks — significantly greater than placebo and outperforming semaglutide-based alternatives in head-to-head comparisons [1][2]. This dual-action mechanism helps regulate appetite, slow gastric emptying, and improve insulin sensitivity, making it particularly effective for patients with obesity or overweight with weight-related comorbidities.

Who Can Use Mounjaro in the UK?

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as type 2 diabetes, hypertension, or sleep apnoea [3]. Your UK prescriber will assess your medical history, current medications, and weight loss goals during your consultation to determine if tirzepatide is clinically appropriate for you. Certain conditions such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 may preclude use.

Mounjaro vs Wegovy: Comparing the UK's Leading Weight Loss Treatments

Both Mounjaro and Wegovy are injectable GLP-1 receptor agonists administered once weekly, but they differ in mechanism and clinical outcomes. Wegovy contains semaglutide, a single GLP-1 receptor agonist, whilst Mounjaro's tirzepatide targets both GIP and GLP-1 receptors. In comparative trials, tirzepatide demonstrated superior weight loss — participants lost an average of 5.5 kg more than those on semaglutide over 40 weeks [2][4].

Wegovy starts at a lower price point and may be suitable for patients new to injectable weight loss medications or those with budget constraints. However, for patients seeking maximum efficacy and willing to invest in their weight loss journey, Mounjaro's dual-action mechanism offers enhanced results. Your UK prescriber will discuss both options during your consultation, considering your medical history, weight loss goals, and tolerance for side effects such as nausea and gastrointestinal discomfort.

Saxenda and Other Injectable Alternatives

Saxenda contains liraglutide, an earlier-generation GLP-1 receptor agonist that requires daily injections rather than weekly administration. Whilst effective for some patients, clinical trials show lower average weight loss compared to weekly tirzepatide or semaglutide [5]. Saxenda may suit patients who prefer starting with a lower-intensity treatment or those who have previously tolerated liraglutide well. All three injectable options require ongoing clinical monitoring and lifestyle modifications including reduced-calorie diet and increased physical activity.

Oral Weight Loss Medications: Orlistat, Mysimba, and Alternatives

Not all patients prefer or are suitable for injectable treatments. Orlistat works by blocking approximately 30% of dietary fat absorption in the intestines, making it effective when combined with a reduced-fat diet [6]. Available as prescription-strength Xenical or lower-dose over-the-counter Alli and Orlos, orlistat suits patients seeking non-injectable options with a well-established safety profile spanning over two decades of UK use.

Mysimba combines naltrexone and bupropion to reduce appetite and food cravings through central nervous system pathways. Clinical trials demonstrated an average weight loss of 5-10% over one year when combined with lifestyle interventions [7]. However, Mysimba requires careful prescriber assessment due to contraindications including uncontrolled hypertension, seizure disorders, and concurrent use of opioid medications. Your UK prescriber will evaluate whether oral or injectable treatments align better with your medical profile and weight loss objectives.

What to Expect During Your Weight Loss Treatment Journey

Injectable treatments like Mounjaro follow a dose-escalation protocol to minimise gastrointestinal side effects. You'll typically start at 2.5 mg weekly for four weeks, then increase to 5 mg for another four weeks, with further increases to 7.5 mg, 10 mg, 12.5 mg, or 15 mg depending on your response and tolerability [1]. Most patients experience mild to moderate nausea during the first few weeks, which typically subsides as your body adjusts to the medication.

Regular follow-up consultations with your UK prescriber are essential to monitor progress, adjust dosing, and address any concerns. Weight loss typically begins within the first month, with maximum effects observed after 16-24 weeks of treatment at your maintenance dose. Combining medication with a structured nutrition plan, regular physical activity, and behavioural support optimises outcomes. Cured Pharmacy provides ongoing clinical support throughout your treatment journey, ensuring you have access to expert guidance when you need it.

Managing Side Effects and Maximising Results

Common side effects of GLP-1 receptor agonists include nausea, diarrhoea, constipation, and reduced appetite. These effects are usually transient and can be managed by eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated. If side effects persist or become severe, contact your prescriber — dose adjustments or temporary treatment pauses may be recommended. Rare but serious side effects such as pancreatitis, gallbladder disease, or severe allergic reactions require immediate medical attention.

Why Choose Cured Pharmacy for Your Weight Loss Treatment

Cured Pharmacy combines clinical excellence with transparent pricing and patient-centred care. Unlike many online providers, we display upfront pricing before you complete your consultation — no hidden fees or surprise charges. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every consultation personally, ensuring you receive safe, evidence-based treatment recommendations tailored to your individual needs.

We guarantee the lowest prices in the UK on genuine, MHRA-licensed medications. Every prescription is dispensed from our GPhC-registered pharmacy (9012511) and delivered in discreet, unmarked packaging with next-day delivery options available. Our patient support team is accessible via phone (+44 116 4646009) during business hours to answer questions about your treatment, delivery, or clinical concerns. With thousands of satisfied patients across the UK, Cured Pharmacy has established itself as a trusted partner in your weight loss journey.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity. NICE Technology Appraisal Guidance. https://www.nice.org.uk/guidance/ta [accessed 13 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
7. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and lifestyle factors.